{"filings":[{"id":1113202,"accession_number":"0001829126-26-006624","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2026-06-17T21:00:17+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nexalin adopts amended bylaws lowering quorum to 1/3, adding forum selection clause","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum for stockholder meetings reduced from majority to one-third of outstanding voting power.","Stockholder action by written consent now permitted, replacing blanket prohibition.","Advance notice rules updated for director nominations and other business, addressing Rule 14a-19.","Added exclusive forum provision: Delaware Chancery for internal claims, federal court for Securities Act claims.","Indemnification, notice, and board structure provisions also revised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":526478,"accession_number":"0001829126-26-005453","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2026-05-19T20:00:16+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Nexalin acquires PONM digital health platform for HALO Clarity for $1.3M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of all PONM shares for $1.3M in Nexalin common stock; first tranche of 959,016 shares issued at closing.","PONM platform, already deployed at UCSD, supports AI-integrated remote monitoring, EHR, and virtual-clinic workflows.","Planned 160-participant FDA pivotal trial for HALO Clarity in moderate-to-severe insomnia; enrollment expected Q2 2026.","GreenLight becomes a meaningful equity holder and enters strategic partnership for development, regulatory, and commercial support.","Collaboration Agreement with GLV provides ongoing development services at $10,000/month for 24-month initial term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93425,"accession_number":"0001829126-26-003765","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Nexalin advances pivotal HALO Clarity insomnia trial toward Q2 2026 enrollment with 160-patient study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered contract with Lindus Health for pivotal study; direct fees ~$944,820 plus pass-through expenses.","160-patient, triple-blinded, sham-controlled trial targeting moderate-to-severe insomnia.","Enrollment expected to begin Q2 2026; study supports planned De Novo FDA submission.","Published peer-reviewed data showed statistically significant improvements vs sham treatment.","Global sleep tech market estimated at $29.3B in 2025, projected to reach $153.7B by 2035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105026,"accession_number":"0001829126-26-001634","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nexalin announces pivotal HALO Clarity trial for insomnia to support FDA de novo submission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["150-patient, triple-blinded, sham-controlled randomized study via decentralized NeuroCare virtual clinic with Lindus Health.","Designed to support planned FDA de novo submission for moderate to severe insomnia treatment.","Builds on prior published 120-patient study showing significant sleep improvements with no adverse effects.","Targets $multi-billion insomnia market; ~30M U.S. adults seek drug-free options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105025,"accession_number":"0001829126-26-000513","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Nexalin receives Nasdaq deficiency notice for non-compliance with $1 minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency letter from Nasdaq on Jan 21, 2026 due to bid price below $1.00 for 30 consecutive business days.","180-day compliance period ends July 20, 2026; must close at $1.00+ for 10 consecutive trading days.","Company states it is not currently considering a reverse stock split to regain compliance.","If compliance not regained, Nasdaq may delist stock; Company expects OTC Markets trading as alternative.","Stock continues to trade on Nasdaq under symbol NXL with no immediate impact on listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121271,"accession_number":"0001829126-25-009755","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nexalin releases December 2025 investor presentation; cash $4.4M, no debt, warrants expired","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Financial snapshot: Cash $4.4M, zero debt, 18.2M common shares, 22.3M fully diluted; warrants expired Sept 2025.","Gen-2 SYNC (15mA) in-clinic device and Gen-3 HALO at-home device with subscription model highlighted.","Regulatory progress: FDA De Novo strategy for Alzheimer's, insomnia; clearances in China, Brazil, Oman, Israel.","Clinical results claim 77% insomnia improvement, 74% depression improvement; Alzheimer's cognitive gains noted.","Go-to-market includes military TBI/PTSD advisory board with former NATO Supreme Commander and DoD official."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121270,"accession_number":"0001829126-25-008140","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nexalin Technology increases ATM offering capacity to $10M from $3.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 to equity distribution agreement with Maxim Group LLC executed Oct 15, 2025.","Maximum aggregate offering price raised from $3.1M to $10M.","As of Oct 15, 2025, approximately $4,273,859 remains available for sale under the ATM program.","Shares sold under shelf registration statement on Form S-3 (File No. 333-286711).","Company is an emerging growth company; common stock trades on Nasdaq under ticker NXL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137918,"accession_number":"0001829126-25-007572","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nexalin Technology warrants expired on Sep 22, 2025; delisted from Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants with $4.15 exercise price expired at 5 PM ET on September 22, 2025.","Nasdaq filed Form 25 to delist the warrants following expiration.","Common stock continues trading on Nasdaq Capital Market under symbol NXL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137917,"accession_number":"0001829126-25-005715","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nexalin Appoints Justin Van Fleet as CFO Effective August 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Van Fleet, CPA, appointed CFO, effective August 1, 2025; previously partner at Marcum LLP.","Van Fleet brings over 20 years public accounting experience, guiding IPOs, M&A, and corporate transactions.","He will oversee financial strategy and reporting as Nexalin's Gen 2 and Gen 3 devices are under FDA review.","CEO Mark White stated Van Fleet's expertise in regulatory compliance and financial management will support growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137916,"accession_number":"0001829126-25-005224","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nexalin appoints Justin Van Fleet as CFO effective August 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Van Fleet, former partner at Marcum LLP, named CFO; base salary $250,000.","One-year term starting August 1, 2025; receives 25,000 shares and options for 130,435 shares.","Options valued at $150,000 based on closing price; 50% vest at 6 months, remainder at 1 year.","Eligible for two discretionary retention bonuses of $20,000 each tied to employment through end of 2025 and term end.","Granted under Nexalin's 2023 Equity Incentive Plan; shares and options unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137915,"accession_number":"0001829126-25-005112","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nexalin stockholders elect all directors, approve equity plan amendment and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; for votes ranged from 6,259,490 to 6,375,246, zero against.","Amendment to 2023 Equity Incentive Plan to increase shares reserved approved: 6,074,244 for, 317,475 against.","Ratification of CBIZ CPAS P.C. as independent auditor for 2025 approved: 10,673,497 for, 99,874 against.","Total shares present at meeting: 11,629,183 of 17,177,929 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155310,"accession_number":"0001829126-25-004343","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nexalin closes partial over-allotment exercise, raising $312K at $1.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 5, 2025, Maxim Group partially exercised its over-allotment option for 240,000 shares.","Shares sold at $1.30 each; aggregate gross proceeds of $312,000 before underwriting discounts.","Closing occurred on June 6, 2025; total shares sold in offering now 4,090,000.","Over-allotment was part of a May 2025 firm commitment public offering initially covering 3,850,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155309,"accession_number":"0001829126-25-003427","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nexalin Technology prices $5.0M public offering of 3.85M shares at $1.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,850,000 shares at $1.30 per share for gross proceeds of ~$5.0M.","Expected closing on May 6, 2025; underwriters granted 45-day option for up to 577,500 additional shares.","Maxim Group LLC is sole book-running manager; net proceeds for working capital, sales, marketing, product development.","Shelf registration statement declared effective April 29, 2025; offering made by prospectus supplement.","Underwriting agreement includes 8.0% cash fee plus up to $110,000 expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155308,"accession_number":"0001829126-25-003349","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nexalin reduces ATM offering size from ~$9.8M to $3.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 5, 2025, Nexalin amended equity distribution agreement with Maxim Group, cutting max aggregate offering price from $9,777,825 to $3,100,000.","ATM program allows sale of common stock from time to time; approximately $3.1M remains available.","Company's shelf registration on Form S-3 remains effective; new prospectus supplement filed same day.","No other changes to the agreement; legal opinion on share legality attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155307,"accession_number":"0001829126-25-002760","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Nexalin replaces Marcum with CBIZ as auditor; prior reports flagged going concern, material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned April 16, 2025; company engaged CBIZ CPAs P.C., which acquired Marcum's attest business.","No disagreements with Marcum on accounting principles or audit scope over the past two fiscal years.","Prior audit reports for FY2024 and FY2023 included explanatory paragraph about substantial doubt on going concern.","Material weaknesses persisted: inadequate segregation of duties and IT user/superuser access controls.","Marcum provided a letter concurring with disclosures, attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173819,"accession_number":"0001829126-25-000757","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SEC declares Nexalin S-1 effective covering up to 2.8M shares from warrant exercises","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registration statement effective for up to 2,798,613 shares of common stock.","Includes 347,250 shares from Maxim Partners warrant (2022 IPO), 2,315,000 from public offering warrants, and 136,363 shares to Maxim as compensation.","All warrants exercisable at $4.15 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190797,"accession_number":"0001829126-24-007235","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nexalin regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on Oct. 31, 2024, confirming compliance with Rule 5550(a)(2).","Regaining compliance removes the risk of delisting from the Nasdaq exchange.","CEO Mark White highlighted the milestone for shareholder value and clinical progress.","Company trades under symbols NXL and NXLIW on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207275,"accession_number":"0001829126-24-006437","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nexalin Technology receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sep 23, 2024 due to bid price below $1.00 for 30 consecutive business days.","Company has 180-day grace period until March 24, 2025 to regain compliance.","To regain compliance, closing bid price must be ≥ $1.00 for at least 10 consecutive business days.","If not compliant by March 24, 2025, may get additional 180-day period by transferring to Nasdaq Capital Market.","No final decisions made on response; company monitoring bid price and evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207274,"accession_number":"0001829126-24-006349","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nexalin appoints Carolyn Shelton as SVP Quality, Regulatory & Clinical Affairs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carolyn Shelton appointed SVP Quality, Regulatory and Clinical Affairs effective Sept 16, 2024.","Base salary of $300,000; annual discretionary bonus of $40,000 based on milestones.","Stock options valued at $60,000 under 2023 Equity Incentive Plan, vesting equally over 3 years from Sept 16, 2025.","Prior roles include VP Regulatory/Quality at Openwater Health, Advanced Sterilization Products, and Medtronic.","Relocation expenses up to $5,000; five weeks paid time off per year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207273,"accession_number":"0001829126-24-006067","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nexalin shareholders elect directors, approve equity plan amendment, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Leslie Bernhard, Mark White, David Owens, Alan Kazden, Ben V. Hu.","Amendment to 2023 Equity Incentive Plan to increase reserved shares approved with 3,063,369 for, 330,557 against.","Marcum LLP ratified as independent auditor for FY 2024 with 6,225,082 for, 38,391 against.","Total shares outstanding at record date: 10,586,562; 6,387,869 present or represented at meeting.","All proposals passed; no broker non-votes disclosed for director election or plan amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207272,"accession_number":"0001829126-24-005111","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SVP of Clinical, Quality, & Regulatory Affairs Michael Nketiah resigns effective Aug 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Nketiah resigned as SVP of Clinical, Quality, & Regulatory Affairs, effective August 16, 2024.","Departure is to pursue another professional opportunity; no disagreement with the company.","He will continue serving until the effective date.","No successor has been named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207271,"accession_number":"0001829126-24-004837","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nexalin raises $5.25M in public offering to regain Nasdaq equity compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on May 16, 2024 for stockholders' equity of $2.327M, below $2.5M minimum.","Submitted compliance plan to Nasdaq on July 1, 2024.","Consummated public offering of 3 million shares for gross proceeds of ~$5.25M.","Company believes it has regained compliance with Nasdaq equity listing rule.","Nasdaq will continue to monitor compliance at next periodic report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207270,"accession_number":"0001829126-24-004580","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nexalin closes $5.25M public offering of 3M shares at $1.75 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 3,000,000 common shares at $1.75/share; gross proceeds approximately $5,250,000.","Maxim Group LLC acted as sole placement agent; paid 8% fee ($420,000) plus $110,000 expense reimbursement.","Proceeds to be used for general corporate purposes including working capital, operating expenses, and capital expenditures.","Offering conducted under effective SEC Form S-1 registration statement (File No. 333-279684) declared effective June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224680,"accession_number":"0001829126-24-004460","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Nexalin Technology prices 3M-share public offering at $1.75, gross proceeds ~$5.25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,000,000 shares of common stock at $1.75 per share; gross proceeds ~$5.25 million.","Maxim Group LLC serving as sole placement agent; fee equals 8% of gross proceeds plus expense reimbursement up to $110,000.","Offering expected to close July 1, 2024, subject to customary closing conditions.","Registration statement on Form S-1 declared effective by SEC on June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224679,"accession_number":"0001829126-24-004310","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nexalin Gen-2 neurostimulation device approved by Brazilian regulator Anvisa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Anvisa approved Nexalin's Gen-2 15 mA neurostimulation device for sale in Brazil.","This is Nexalin's second regulatory approval outside China in 2024.","Brazil has >215M population, >35M with mental health disorders; 9th largest economy.","CEO says approval is springboard into other South American markets; distributor talks underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224678,"accession_number":"0001829126-24-003603","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nexalin receives Nasdaq delisting notice for stockholders' equity deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Nexalin on May 16, 2024 of non-compliance with minimum $2.5M equity requirement.","Stockholders' equity reported as $2,326,987 in Q1 2024 Form 10-Q.","Company has until July 1, 2024 to submit a compliance plan for a possible 180-day extension.","No immediate effect on listing; common stock continues trading on Nasdaq under symbol NXL.","There is no assurance the company can regain compliance with Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224677,"accession_number":"0001829126-24-002788","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nexalin regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on April 23, 2024, of compliance with Rule 5550(a)(2).","Regained compliance with minimum bid price requirement for continued listing.","CEO Mark White expressed gratitude to shareholders and reaffirmed commitment to neurostimulation mission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224676,"accession_number":"0001829126-24-002415","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nexalin CEO details clinical progress, Gen-3 HALO headset, and government market expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive clinical results from UCSD study: Gen-2 tACS reduced post-concussive and PTSD symptoms in veterans with mTBI.","Published insomnia study showed statistically significant sleep improvements vs placebo; 6 additional peer-reviewed studies on 15mA waveform.","New Gen-3 HALO Clarity headset with DIFS technology enables at-home treatment under Virtual Clinic remote physician monitoring; ahead of schedule.","Formed military and government advisory board led by former Deputy Assistant Secretary of Defense; targeting DoD, VA, HHS markets.","Received regulatory approval in Oman with sales to new Mental Health Center; patents extended through 2040 with four key patents and three pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243948,"accession_number":"0001829126-24-001749","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nexalin shareholders approve reverse stock split amendment with board discretion on ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held March 7, 2024; 4,587,248 shares present (61.7% of outstanding).","Proposal 1 (reverse split amendment): 4,304,448 for, 259,736 against, 23,064 abstained — approved.","Board retains authority to determine if and when to file the amendment and the split ratio.","Proposal 2 (adjournment): 4,442,221 for, 112,047 against, 32,980 abstained — approved.","No specific split ratio disclosed; potential to regain compliance with Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261359,"accession_number":"0001829126-23-007308","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nexalin receives Nasdaq delisting notice; bid price and equity rules non-compliant","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Nexalin on May 10, 2023 of bid price deficiency; 180-day cure period expired Nov 6, 2023 without compliance.","Second 180-day period denied because Company no longer meets $5M minimum stockholder equity initial listing requirement.","Company appealed to Nasdaq Hearings Panel; trading stay granted while appeal pending.","Company plans to submit a compliance plan addressing bid price and equity requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278602,"accession_number":"0001829126-23-006353","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nexalin CFO Marilyn Elson resigns, effective Nov 1, 2023; to remain as Controller","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Marilyn Elson submitted resignation on September 21, 2023, effective November 1, 2023.","Elson will continue as CFO until Nov 1, then serve as Controller thereafter.","No disagreements between Elson and the company; resignation not related to operations or accounting.","Mark White, CEO, signed the 8-K on September 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296816,"accession_number":"0001829126-23-003881","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nexalin forms JV with Wider Come to commercialize tACS devices in Asia; Wider funds ops and 4 trials","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["JV ownership: Wider 52%, Nexalin 48%; will market Gen-2 tACS devices in China and Asia Pacific.","Wider to fund all JV operating expenses for 12 months, then pro rata funding.","Wider obligated to fund and conduct four clinical trials (insomnia, depression, other) using Gen-2 devices.","Previously Wider was an authorized distributor; role now expanded to include clinical development.","NMPA approval for insomnia and depression already in place for tACS device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296815,"accession_number":"0001829126-23-003481","cik":1527352,"company_name":"Nexalin Technology, Inc.","ticker":"NXL","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nexalin Technology receives Nasdaq bid price deficiency notice; has 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Nexalin on May 10, 2023 that its common stock closing bid price fell below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until November 6, 2023, to regain compliance by achieving $1.00 or more for 10 consecutive business days.","If not compliant by Nov 6, may transfer listing to Nasdaq Capital Market for an additional 180-day grace period.","Company says it will monitor options but no decisions made; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12143150.4380322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}